CliffBio
small molecule

CEFUROXIME SODIUM

CEFUROXIME SODIUM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCEFUROXIME SODIUM
Active ingredientCEFUROXIME SODIUM
StrengthEQ 750MG BASE/VIAL
Dosage formINJECTABLE
RouteINTRAMUSCULAR, INTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2001
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.